The Regeneron Pharmaceuticals, Inc. line shows up 86 times in the congressional disclosure record between 2013 and 2026, filed by 20 members: 47 purchases against 39 sales. On balance the chamber has been net buyers, and the purchases sit up 10.6% against the latest close.
*Purchases only, weighted by the midpoint of each disclosed dollar band and marked to the latest close. Filings report a range, never a share count, so this follows the stock rather than anyone's position size.
Members ranked by how their reported REGN purchases have moved since, over roughly the last three years, weighted by disclosed band midpoint and marked to the latest close.
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2017-11-28 | Rohit Khanna | SELL | $1K–$15K | $366.00 | $827.72 2026-09-04 | -126.2% exit |
| 2017-11-22 | Peter Welch | BUY | $1K–$15K | $387.54 | $807.67 2026-10-26 | +108.4% |
| 2017-11-20 | Peter Welch | BUY | $1K–$15K | $385.22 | $807.67 2026-10-26 | +109.7% |
| 2017-11-08 | Peter Welch | BUY | $1K–$15K | $415.17 | $807.67 2026-10-26 | +94.5% |
| 2017-11-07 | Peter Welch | BUY | $1K–$15K | $404.39 | $807.67 2026-10-26 | +99.7% |
| 2017-11-06 | Peter Welch | BUY | $1K–$15K | $406.63 | $807.67 2026-10-26 | +98.6% |
| 2017-11-03 | Peter Welch | BUY | $1K–$15K | $408.41 | $807.67 2026-10-26 | +97.8% |
| 2017-07-18 | Rohit Khanna | SELL | $1K–$15K | $497.63 | $827.72 2026-09-04 | -66.3% exit |
| 2017-07-05 | Rohit Khanna | BUY | $1K–$15K | $497.00 | $827.72 2026-09-04 | +66.5% |
| 2017-05-16 | Sheldon Whitehouse | BUY | $1K–$15K | $454.75 | $827.72 2026-09-04 | +82.0% |
| 2017-04-11 | Francis Rooney | BUY | $1K–$15K | $367.07 | $827.72 2026-09-04 | +125.5% |
| 2016-10-04 | Michael T. McCaul | SELL | $1K–$15K | $397.20 | $827.72 2026-09-04 | -108.4% exit |
| 2016-10-04 | Michael T. McCaul | SELL | $1K–$15K | $397.20 | $827.72 2026-09-04 | -108.4% exit |
| 2016-09-06 | Sheldon Whitehouse | BUY | $1K–$15K | $398.31 | $827.72 2026-09-04 | +107.8% |
| 2016-09-06 | Sheldon Whitehouse | BUY | $1K–$15K | $398.31 | $827.72 2026-09-04 | +107.8% |
| 2016-05-24 | Sheldon Whitehouse | BUY | $1K–$15K | $397.70 | $827.72 2026-09-04 | +108.1% |
| 2016-02-26 | K. Michael Conaway | SELL | $1K–$15K | $394.23 | $827.72 2026-09-04 | -110.0% exit |
| 2016-01-29 | James B. Renacci | BUY | $1K–$15K | $420.09 | $827.72 2026-09-04 | +97.0% |
| 2016-01-28 | James B. Renacci | BUY | $1K–$15K | $415.11 | $827.72 2026-09-04 | +99.4% |
| 2016-01-28 | K. Michael Conaway | SELL | $1K–$15K | $415.11 | $827.72 2026-09-04 | -99.4% exit |
| 2016-01-27 | James B. Renacci | BUY | $1K–$15K | $434.16 | $827.72 2026-09-04 | +90.7% |
| 2015-12-18 | Michael T. McCaul | SELL | $1K–$15K | $544.23 | $807.67 2026-10-26 | -48.4% exit |
| 2015-12-18 | Michael T. McCaul | SELL | $1K–$15K | $544.23 | $807.67 2026-10-26 | -48.4% exit |
| 2015-12-07 | James B. Renacci | BUY | $1K–$15K | $546.61 | $807.67 2026-10-26 | +47.8% |
| 2015-09-30 | James B. Renacci | BUY | $1K–$15K | $465.14 | $807.67 2026-10-26 | +73.6% |
| 2015-08-10 | James B. Renacci | BUY | $1K–$15K | $581.00 | $807.67 2026-10-26 | +39.0% |
| 2015-06-18 | James B. Renacci | BUY | $1K–$15K | $527.97 | $807.67 2026-10-26 | +53.0% |
| 2015-06-17 | James B. Renacci | BUY | $1K–$15K | $512.89 | $807.67 2026-10-26 | +57.5% |
| 2015-06-17 | James B. Renacci | BUY | $1K–$15K | $512.89 | $807.67 2026-10-26 | +57.5% |
| 2015-05-26 | Steve Chabot | BUY | $1K–$15K | $506.63 | $807.67 2026-10-26 | +59.4% |
| 2015-04-16 | Michael T. McCaul | SELL | $50K–$100K | $457.42 | $807.67 2026-10-26 | -76.6% exit |
| 2015-04-16 | Michael T. McCaul | SELL | $50K–$100K | $457.42 | $807.67 2026-10-26 | -76.6% exit |
| 2015-03-27 | Michael T. McCaul | SELL | $50K–$100K | $454.50 | $807.67 2026-10-26 | -77.7% exit |
| 2015-03-27 | Michael T. McCaul | SELL | $50K–$100K | $454.50 | $807.67 2026-10-26 | -77.7% exit |
| 2014-01-30 | Susan M Collins | SELL | $1K–$15K | $292.97 | $807.67 2026-10-26 | -175.7% exit |
| 2013-11-29 | SUSAN M COLLINS | SELL | $1K–$15K | $293.86 | $807.67 2026-10-26 | -174.8% exit |
Buys are marked to the latest close and treated as open. A sell tagged rt closes an earlier disclosed buy in the same name. exit shows how the stock moved after the member sold.
20 members of the U.S. House and Senate have disclosed Regeneron Pharmaceuticals, Inc. transactions under the STOCK Act — 47 purchases and 39 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a REGN purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Notional-weighted, lawmakers' disclosed REGN buys are up 10.6% versus the latest close of $827.72. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded REGN and how it performed.